Sakura Finetek Europe launched the Sakura Pathology Network (SPN), a European network for early-career pathologists at the European Congress of Pathology (ECP) 2026 in September in Stockholm. Its founding members represented different countries, institutions and areas of expertise or interest.
Vetter, the contract development and manufacturing organisation (CDMO) headquartered in Ravensburg, Germany, is expanding its commercial fill-and-finish network. The company says the investment programme will strengthen its global manufacturing operations and support the evolving needs of pharmaceutical and biotechnology customers. The long-term plan includes ten additional commercial filling lines.
BioMed X has started a new research team at its institute in New Haven, Connecticut, to investigate the brain circuit mechanisms underlying anhedonia. The aim is to identify biomarkers and therapeutic targets. The project is run in collaboration with the pharmaceutical company AbbVie and was announced on 29 September 2026. It is titled ‘Circuit-Based Model […]
ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, and The Protein Society, an international, not-for-profit, scholarly society, with the mission to provide forums for the advancement of research into protein structure, function, design and applications, announced the keynote speakers for Protein Sciences in Drug Discovery 2026.
Bruker Corporation has announced a majority investment in MIMETAS B.V., a Leiden-based developer of organ-on-a-chip platforms and human tissue and disease models used in drug discovery and development. The investment extends Bruker’s post-genomic portfolio into microphysiological systems (MPS), also referred to as new approach methodologies (NAMs), which are built on human physiology-relevant model systems rather […]
Celonic AG, a Swiss-based biologics contract development and manufacturing organisation (CDMO), and Leukocare AG, a German provider of drug product development services, have announced a collaboration aimed at supporting biopharmaceutical companies developing complex biologics.
A US-based team has developed a method for detecting Zika virus and hepatitis C virus (HCV) RNA directly from dried whole blood, bypassing the extraction and purification steps that have long constrained point-of-care molecular diagnostics. The work, published in Science Advances on 4 September 2026, reports sensitivities comparable to centralised PCR-based testing using only a […]
BioMed X, an organisation focused on sourcing scientific talent and developing early-stage biomedical solutions for pharmaceutical partners, has announced that it will move its global headquarters to LAB22, a newly constructed building within Heidelberg Innovation Park (hip), Germany. Alongside the relocation, the company has entered into a partnership with BioLabs, a provider of shared laboratory […]
Sheffield-based biotechnology company SynGenSys has appointed four heads of department to its commercial and scientific teams, as the firm moves to scale up commercial delivery of its synthetic gene promoter technologies.
HeartBeat.bio AG, a Vienna-based developer of human cardiac organoid technology, and Cubase Bio™, a Stockholm-based genomics company, have entered a research collaboration aimed at applying three-dimensional spatial transcriptomics to the study of myocardial fibrosis and heart failure.